Skip to main content
GOSS
NASDAQ Life Sciences

D. E. Shaw Entities Reduce Stake in Gossamer Bio by Over $900K Post-Debt Exchange

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.17
Mkt Cap
$81.98M
52W Low
$0.14
52W High
$3.87
52W Position info
21% above low
Off High info
96% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

GOSS sits 21% above its 52-week low of $0.14.

Summary

D. E. Shaw & Co. entities have significantly reduced their stake in Gossamer Bio, selling over $900,000 in shares following the company's distressed debt exchange.


Key Events · Ownership and Investor Activity · GOSS

  • Significant Share Sales by Institutional Investor

    D. E. Shaw & Co. entities sold 5,445,469 common shares between June 12 and July 1, 2026, for an estimated value of over $925,000.

  • Stake Reduction Post-Debt Exchange

    These sales occurred after Gossamer Bio completed a distressed debt exchange, converting $181.05 million of convertible notes into equity, which resulted in massive dilution.

  • Current Beneficial Ownership

    Following these transactions, D. E. Shaw & Co., L.P. and related entities beneficially own 40,630,726 shares, representing 8.3% of the outstanding common stock.


Analysis · GOSS · Life Sciences

D. E. Shaw & Co. entities, significant institutional investors, have sold approximately $925,000 worth of Gossamer Bio common stock over the past month. This reduction in stake, representing over 1% of the company's market capitalization and 13% of their prior holdings, occurs shortly after the company completed a highly dilutive distressed debt exchange. The sales by a major investor suggest a lack of confidence following the recent financial restructuring.

How filings like this one have moved

In the 30 days to Oct 21, 2026, 29.1% of the 1524 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GOSS was trading at $0.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $82M. The 52-week trading range was $0.14 to $3.87. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GOSS - Latest Insights

GOSS
Sep 23, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.19
Real-time Price: $9.95 info
Change: -$1.24 (-11%) info
Market Cap: $60.825M info
GOSS
Sep 23, 2026, 4:01 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $11.00
Real-time Price: $9.95 info
Change: -$1.05 (-10%) info
Market Cap: $60.825M info
GOSS
Sep 16, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $10.93
Real-time Price: $9.95 info
Change: -$0.9759 (-9%) info
Market Cap: $60.825M info
GOSS
Sep 11, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.1562
Real-time Price: $9.95 info
Change: Reverse Stock Split info
Market Cap: $60.825M info
GOSS
Sep 11, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $0.1562
Real-time Price: $9.95 info
Change: Reverse Stock Split info
Market Cap: $60.825M info